Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose QP-6211 for postoperative analgesia in unilateral hallux valgus surgery
CTR20242499Phase 2Completed
- Sponsor
- ClearPoint Biotech
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QP-6211 in postoperative pain, sponsored by ClearPoint Biotech. Started Jul 2024; status: completed.
02
Drugs
QP-6211
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20242499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242499.